2025 Q4 -tulosraportti
Vain PDF
8 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 102 | - | - | ||
| 767 | - | - | ||
| 1 939 | - | - | ||
| 920 | - | - |
Ylin
15,58VWAP
Alin
14,24VaihtoMäärä
16,7 1 129 353
VWAP
Ylin
15,58Alin
14,24VaihtoMäärä
16,7 1 129 353
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 150 580 | 1 150 580 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 150 580 | 1 150 580 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·22 t sittenShort 1,06 % it rises
·2 t sittenSorry - it was not the intention to belittle or write at a low level. I "enjoy" reading your posts, and it's good to have more eyes. I'll tone down the rhetoric :) But what is it they need to show first, which they haven't done with acadia and jazz? And does it make sense to wait to buy a stock UNTIL they have proven something, and then miss out on the price increase? It's the potential we're buying now. And I don't think the potential is reflected in the price right now at all. I don't think the risk is THAT big... They have after all many horses to ride on! And more in their library that we don't even know/haven't named yet.
·2 t sitten · MuokattuThat they can handle the new very high risk profile with 3 preclinical projects they have chosen to start in Phase I at the same time. And for me, in biotech, it makes a LOT of sense to wait - it's all a risk/reward analysis. Before the agreements, they were at a price of 2-4 - lots of potential - but high risk. Then they get the agreements - still great potential - but now cash in hand. Price 11-12 - new agreements and new projects - still great potential but less risk - 25-30. The potential may have always been a price of 200+ - and price vs potential then reflects the risk/reward-ratio one is comfortable with. And here some are fine with 25-30 now - I am not. We probably see the same potential - so it's the risk we value differently - I would give 12-15 for that potential with the current risk - others have been willing to give 25-30 for the same potential. They need a lot of money until 2030 and as I have written in another post, I think they will need more than the USD 90-100 mill they themselves have announced - and I also don't think they can get it covered entirely with milestones and new projects. Another Jazz-like sale will naturally help with that, but it's far from enough. There will be a long time between the upcoming fairly certain milestones on their agreements and the next one - and still a risk that partner projects will be stopped. Saniona has been going for many many years - but they still haven't had a product brought to market that today gives them ongoing royalty - that is concerning regarding the assessment of the total validity of their projects regarding whether they are able to find something strong enough to go all the way. They have had a couple of nice spinouts and recently some good deals - but for me, more is needed. And that is the risk I clearly see differently than most other Saniona shareholders. And thanks for clarifying the tone :-). Have a good weekend.
·1 päivä sittenDoes it look like a shorter day? Then it would be nice if we could refrain from selling!
·2 päivää sittenIt is No comfort but glad that a Jonas Bohr has now reached the point where something is completely wrong, and someone will constantly push down the value. Many posts with views on this have otherwise received harsh treatment and comments about how ridiculous and negative they were. There are some who have talked it up tremendously and approved teso many times, it is the exact opposite of what was needed. Several of them go after the man and not the post And it is now very clearly seen that they did completely the wrong thing now. From now on, some of these hyper-fools must stop their stupid-naive comments and acknowledge it is a long journey upwards, but the short sellers and other fraudsters must do it legally with full backing from their superiors who direct them from one scam after another. Just come again with comments but first look at the price before you write.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
8 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22 t sittenShort 1,06 % it rises·2 t sittenSorry - it was not the intention to belittle or write at a low level. I "enjoy" reading your posts, and it's good to have more eyes. I'll tone down the rhetoric :) But what is it they need to show first, which they haven't done with acadia and jazz? And does it make sense to wait to buy a stock UNTIL they have proven something, and then miss out on the price increase? It's the potential we're buying now. And I don't think the potential is reflected in the price right now at all. I don't think the risk is THAT big... They have after all many horses to ride on! And more in their library that we don't even know/haven't named yet.·2 t sitten · MuokattuThat they can handle the new very high risk profile with 3 preclinical projects they have chosen to start in Phase I at the same time. And for me, in biotech, it makes a LOT of sense to wait - it's all a risk/reward analysis. Before the agreements, they were at a price of 2-4 - lots of potential - but high risk. Then they get the agreements - still great potential - but now cash in hand. Price 11-12 - new agreements and new projects - still great potential but less risk - 25-30. The potential may have always been a price of 200+ - and price vs potential then reflects the risk/reward-ratio one is comfortable with. And here some are fine with 25-30 now - I am not. We probably see the same potential - so it's the risk we value differently - I would give 12-15 for that potential with the current risk - others have been willing to give 25-30 for the same potential. They need a lot of money until 2030 and as I have written in another post, I think they will need more than the USD 90-100 mill they themselves have announced - and I also don't think they can get it covered entirely with milestones and new projects. Another Jazz-like sale will naturally help with that, but it's far from enough. There will be a long time between the upcoming fairly certain milestones on their agreements and the next one - and still a risk that partner projects will be stopped. Saniona has been going for many many years - but they still haven't had a product brought to market that today gives them ongoing royalty - that is concerning regarding the assessment of the total validity of their projects regarding whether they are able to find something strong enough to go all the way. They have had a couple of nice spinouts and recently some good deals - but for me, more is needed. And that is the risk I clearly see differently than most other Saniona shareholders. And thanks for clarifying the tone :-). Have a good weekend.
- ·1 päivä sittenDoes it look like a shorter day? Then it would be nice if we could refrain from selling!
- ·2 päivää sittenIt is No comfort but glad that a Jonas Bohr has now reached the point where something is completely wrong, and someone will constantly push down the value. Many posts with views on this have otherwise received harsh treatment and comments about how ridiculous and negative they were. There are some who have talked it up tremendously and approved teso many times, it is the exact opposite of what was needed. Several of them go after the man and not the post And it is now very clearly seen that they did completely the wrong thing now. From now on, some of these hyper-fools must stop their stupid-naive comments and acknowledge it is a long journey upwards, but the short sellers and other fraudsters must do it legally with full backing from their superiors who direct them from one scam after another. Just come again with comments but first look at the price before you write.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 102 | - | - | ||
| 767 | - | - | ||
| 1 939 | - | - | ||
| 920 | - | - |
Ylin
15,58VWAP
Alin
14,24VaihtoMäärä
16,7 1 129 353
VWAP
Ylin
15,58Alin
14,24VaihtoMäärä
16,7 1 129 353
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 150 580 | 1 150 580 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 150 580 | 1 150 580 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
8 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22 t sittenShort 1,06 % it rises·2 t sittenSorry - it was not the intention to belittle or write at a low level. I "enjoy" reading your posts, and it's good to have more eyes. I'll tone down the rhetoric :) But what is it they need to show first, which they haven't done with acadia and jazz? And does it make sense to wait to buy a stock UNTIL they have proven something, and then miss out on the price increase? It's the potential we're buying now. And I don't think the potential is reflected in the price right now at all. I don't think the risk is THAT big... They have after all many horses to ride on! And more in their library that we don't even know/haven't named yet.·2 t sitten · MuokattuThat they can handle the new very high risk profile with 3 preclinical projects they have chosen to start in Phase I at the same time. And for me, in biotech, it makes a LOT of sense to wait - it's all a risk/reward analysis. Before the agreements, they were at a price of 2-4 - lots of potential - but high risk. Then they get the agreements - still great potential - but now cash in hand. Price 11-12 - new agreements and new projects - still great potential but less risk - 25-30. The potential may have always been a price of 200+ - and price vs potential then reflects the risk/reward-ratio one is comfortable with. And here some are fine with 25-30 now - I am not. We probably see the same potential - so it's the risk we value differently - I would give 12-15 for that potential with the current risk - others have been willing to give 25-30 for the same potential. They need a lot of money until 2030 and as I have written in another post, I think they will need more than the USD 90-100 mill they themselves have announced - and I also don't think they can get it covered entirely with milestones and new projects. Another Jazz-like sale will naturally help with that, but it's far from enough. There will be a long time between the upcoming fairly certain milestones on their agreements and the next one - and still a risk that partner projects will be stopped. Saniona has been going for many many years - but they still haven't had a product brought to market that today gives them ongoing royalty - that is concerning regarding the assessment of the total validity of their projects regarding whether they are able to find something strong enough to go all the way. They have had a couple of nice spinouts and recently some good deals - but for me, more is needed. And that is the risk I clearly see differently than most other Saniona shareholders. And thanks for clarifying the tone :-). Have a good weekend.
- ·1 päivä sittenDoes it look like a shorter day? Then it would be nice if we could refrain from selling!
- ·2 päivää sittenIt is No comfort but glad that a Jonas Bohr has now reached the point where something is completely wrong, and someone will constantly push down the value. Many posts with views on this have otherwise received harsh treatment and comments about how ridiculous and negative they were. There are some who have talked it up tremendously and approved teso many times, it is the exact opposite of what was needed. Several of them go after the man and not the post And it is now very clearly seen that they did completely the wrong thing now. From now on, some of these hyper-fools must stop their stupid-naive comments and acknowledge it is a long journey upwards, but the short sellers and other fraudsters must do it legally with full backing from their superiors who direct them from one scam after another. Just come again with comments but first look at the price before you write.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 102 | - | - | ||
| 767 | - | - | ||
| 1 939 | - | - | ||
| 920 | - | - |
Ylin
15,58VWAP
Alin
14,24VaihtoMäärä
16,7 1 129 353
VWAP
Ylin
15,58Alin
14,24VaihtoMäärä
16,7 1 129 353
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 150 580 | 1 150 580 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 150 580 | 1 150 580 | 0 | 0 |